Naveris Announces New Data Featuring NavDx® in Oral Highlight and Poster Presentations at Upcoming ASTRO and AAO-HNSF 2023 Meetings

WALTHAM, Mass.–(BUSINESS WIRE)–Naveris, Inc. , the leader in precision oncology diagnostics for viral-induced cancers, today announced that the company will be attending The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNSF) 2023 Annual Meeting in Nashville, Tenn., from September 30-October 4 and The American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting in San Diego, Calif., from October 1-4.

Naveris will be exhibiting at both meetings, providing the latest information on NavDx®, Naveris’ proprietary flagship blood test for tumor tissue modified viral (TTMV®)-HPV DNA. NavDx is the first and only clinically validated circulating tumor HPV DNA blood test that provides a non-invasive and precise method for detecting molecular residual disease (MRD) before there is clinical or radiographical evidence of cancer recurrence.

The company will also highlight its TTMV-DNA platform in abstracts selected for oral presentation at both meetings.

“There is growing enthusiasm for the use of NavDx in daily practice across the continuum of HPV-driven OPSCC care, especially in the surveillance setting,” said Barry M. Berger, MD, Chief Medical Officer of Naveris. “We look forward to this new data at the upcoming AAO-HNSF and ASTRO conferences, adding to the accumulation of compelling evidence that is driving clinical adoption of NavDx.”

Following are details of the abstract that has been accepted for an oral presentation at AAO-HNSF 2023:

• Detecting HPV-Driven Oropharyngeal Carcinoma Recurrence Using Circulating Tumor HPV DNA
  
  Authors: Thakkar, P. G., et al.
  
  Presenting Author: Shakhtour, L.
  
  Scientific Session: Scientific Oral Presentations 3 – Head and Neck Surgery
  
  Session Date/Time: October 2, 2023 | 8:00AM – 9:00AM CST

Following are details of the abstract that has been accepted for an oral presentation at ASTRO 2023:

• A phase II trial evaluating rapid mid-treatment nodal shrinkage to select for adaptive deescalation in p16+ oropharyngeal cancer patients undergoing definitive chemoradiation
  
  Authors: Kim, J., et al.
  
  Presenter: Kim, J.
  
  Scientific Session: SS 23, H&N 2: Virus-Associated Head & Neck Cancers: From Screening to Treatment
  
  Session Date/Time: October 3, 2023 | 2:30PM – 3:30PM PST

This second abstract was also selected for inclusion in the Head & Neck Cancer Science Highlights session, taking place Tuesday, October 3, 2023 from 8:00 AM – 8:30 AM at the San Diego Convention Center, Room 1, as part of Session SH 03: Science Highlights 3 – Head & Neck Cancer.

Naveris and NavDx will be on exhibit at AAO-HNSF 2023 at Booth #608 and at ASTRO 2023 at Booth #3325.

About Naveris

Naveris is a privately held, commercial stage, precision oncology diagnostics company with facilities in Massachusetts and North Carolina. Since its founding in 2017, Naveris has been committed to improving outcomes for the millions of people at risk of developing viral-induced cancers with novel molecular diagnostics that enable earlier cancer detection. The company operates high-complexity testing clinical laboratories that are accredited by the College of American Pathologists and the New York State Department of Health Wadsworth Center, and are certified under CLIA. For more information on Naveris and the clinical impact of NavDx, please visit www.naveris.com and www.NavDx.com.

Contacts

Megan Kernan

ICR Westwicke Healthcare PR

Tel: 646.677.1870

[email protected]